Syndecan-4-dependent signaling in the inhibition of endotoxin-induced endothelial adherence of neutrophils by antithrombin

Thrombosis and Haemostasis

Volumn 90, Issue 6, 2003, Pages 1150-1157

  Kaneider, Nicole C ^a   Förster, Ellen ^a   Mosheimer, Birgit ^a   Sturn, Daniel H ^a   Wiedermann, Christian J ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Antithrombin; Neutrophils; Syndecan 4

Indexed keywords

ANTIBODY; ANTITHROMBIN; CHONDROITIN ABC LYASE; ENDOTOXIN; FONDAPARINUX; GLYCOSAMINOGLYCAN; HEPARIN; HEPARIN LYASE; HEPARIN LYASE I; INTERLEUKIN 1; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; PENTASACCHARIDE; STRESS ACTIVATED PROTEIN KINASE; SYNDECAN 4; SYNDECAN 4 ANTIBODY; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BINDING SITE; CELL ADHESION; CONTROLLED STUDY; CULTURE MEDIUM; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ENDOTHELIUM CELL; ENDOTHELIUM LESION; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; MOLECULAR INTERACTION; NEUTROPHIL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STRESS; UMBILICAL VEIN; VASCULAR ENDOTHELIUM; WESTERN BLOTTING;

EID: 0348108109     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/th03-03-0184     Document Type: Article

References (47)

1. Gotte M, Joussen AM, Klein C, et al. Role of syndecan-1 in leukocyte-endothelial interactions in the ocular vasculature. Invest Ophthalmol Vis Sci 2002; 43: 1135-41.
2. Hoogewerf AJ, et al. Glycosaminoglycans mediate cell surface oligomerization of chemokines. Biochemistry 1997; 36: 13570-8.
3. Webb LM, Ehrengruber MU, Clark-Lewis I, et al. Binding to heparan sulfate or heparin enhances neutrophil responses to interleukin 8. Proc Natl Acad Sci USA 1993; 90: 7158-62.
4. Peter K, et al. Heparin inhibits ligand binding to the leukocyte integrin Mac-1 (CD11b/CD18). Circulation 1999; 100: 1533-9.
5. Diamond MS, et al. Heparin is an adhesive ligand for the leukocyte integrin Mac-1 (CD11b/CD1). J Cell Biol 1995; 130: 1473-82.
6. Giuffre L, Cordey AS, Monai N, et al. Monocyte adhesion to activated aortic endothelium: Role of L-selectin and heparan sulfate proteoglycans. J Cell Biol 1997; 136: 945-56.
7. Handa K, et al. Selectin GMP-140 (CD62; PADGEM) binds to sialosyl-Le(a) and sialosyl- Le(x), and sulfated glycans modulate this binding. Biochem Biophys Res Commun 1991; 181: 1223-30.
8. Hoffmann JN, Vollmar B, Romisch J, et al. Antithrombin effects on endotoxin-induced microcirculatory disorders are mediated mainly by its interaction with microvascular endothelium. Crit Care Med 2002; 30: 218-25.
9. Inthorn D, et al. Antithrombin III supplementation in severe sepsis: Beneficial effects on organ dysfunction. Shock 1997; 8: 328-34.
10. Kaneider NC, et al. Syndecan-4 mediates antithrombin-induced chemotaxis of human peripheral blood lymphocytes and monocytes. J Cell Sci 2002; 115: 227-36.
11. Kaneider NC, et al. Syndecan-4 as antithrombin receptor of human neutrophils. Biochem Biophys Res Commun 2001; 287: 42-6.
12. Dunzendorfer S, Kaneider N, Rabensteiner A, et al. Cell-surface heparan sulfate proteoglycan-mediated regulation of human neutrophil migration by the serpin antithrombin III. Blood 2001; 97: 1079-85.
13. Horie S, Ishii H, Kazama M. Heparin-like glycosaminoglycan is a receptor for antithrombin III-dependent but not for thrombin-dependent prostacyclin production in human endothelial cells. Thromb Res 1990; 59: 895-904.
14. Olson ST, et al. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement. J Biol Chem 1992; 267: 12528-38.
15. Yanada M, Kojima T, Ishiguro K, et al. Impact of antithrombin deficiency in thrombogenesis: Lipopolysaccharide and stress-induced thrombus formation in heterozygous antithrombin-deficient mice. Blood 2002; 99: 2455-8.
16. Hoffmann JN, et al. Adverse effect of heparin on antithrombin action during endotoxemia: Microhemodynamic and cellular mechanisms. Thromb Haemost 2002; 88: 242-52.
17. Damus PS, Rosenberg RD. Antithrombin-heparin cofactor. Methods Enzymol 1976; 45: 653-69.
18. Kaneider NC, et al. Reversal of thrombin-induced deactivation of CD39/ATPDase in endothelial cells by HMG-CoA reductase inhibition: Effects on Rho- GTPase and adenosine nucleotide metabolism. Arterioscler Thromb Vasc Biol 2002; 22: 894-900.
19. Hsu HY, Wen MH. Lipopolysaccharide-mediated reactive oxygen species and signal transduction in the regulation of interleukin-1 gene expression. J Biol Chem 2002; 277: 22131-9.
20. Carrell RW. How serpins are shaping up. Science 1999; 285: 1861.
21. Uchiba M, Okajima K, Murakami K, et al. Attenuation of endotoxin-induced pulmonary vascular injury by antithrombin III. Am J Physiol 1996; 270: L921-L930.
22. Okada Y, Zuo XJ, Marchevsky AM, et al. Antithrombin III treatment improves parameters of acute inflammation in a highly histoincompatible model of rat lung allograft rejection. Transplantation 1999; 67: 526-8.
23. Oelschlager C, et al. Antithrombin III inhibits nuclear factor kappaB activation in human monocytes and vascular endothelial cells. Blood 2002; 99: 4015-20.
24. De La Cadena RA, et al. Activation of the kallikrein-kinin system after endotoxin administration to normal human volunteers. Blood 1993; 81: 3313-7.
25. Schoeffel U, Lausen M, Ruf G, et al. The overwhelming inflammatory response and the role of endotoxin in early sepsis. Prog Clin Biol Res 1989; 308: 371-6.
26. Bick RL. Disseminated intravascular coagulation: Pathophysiological mechanisms and manifestations. Semin Thromb Hemost 1998; 24: 3-18.
27. Parrillo JE. Pathogenetic mechanisms of septic shock. N Engl J Med 1993; 328: 1471-7.
28. McCuskey RS, Urbaschek R, Urbaschek B. The microcirculation during endotoxemia. Cardiovasc Res 1996; 32: 752-63.
29. Lowry SF. Cytokine mediators of immunity and inflammation. Arch Surg 1993; 128: 1235-41.
30. Lam C, et al. Microvascular perfusion is impaired in a rat model of normotensive sepsis. J Clin Invest 1994; 94: 2077-83.
31. Nooteboom A, Van Der Linden CJ, Hendriks T. Tumor necrosis factor-alpha and interleukin-1beta mediate endothelial permeability induced by lipopolysaccharide-stimulated whole blood. Crit Care Med 2002; 30: 2063-8.
32. Ostrovsky L, Woodman RC, Payne D, et al. Antithrombin III prevents and rapidly reverses leukocyte recruitment in ischemia/reperfusion. Circulation 1997; 96: 2302-10.
33. Johnston B, et al. Differential roles of selectins and the alpha4-integrin in acute, subacute, and chronic leukocyte recruitment in vivo. J Immunol 1997; 159: 4514-23.
34. Granger DN, Kubes P. The microcirculation and inflammation: Modulation of leukocyte-endothelial cell adhesion. J Leukoc Biol 1994; 55: 662-75.
35. Kaneider NC, et al. Sphingosine kinase-dependent directional migration of leukocytes in response to phorbol ester. Biochem Biophys Res Commun 2002; 297: 806-10.
36. Luo J, Kato M, Wang H, et al. Heparan sulfate and chondroitin sulfate proteoglycans inhibit E-selectin binding to endothelial cells. J Cell Biochem 2001; 80: 522-31.
37. Salmivirta M, Lidholt K, Lindahl U. Heparan sulfate: A piece of information. FASEB J 1996; 10: 1270-9.
38. Wadstrom T, Ljungh A. Glycosaminoglycan-binding microbial proteins in tissue adhesion and invasion: Key events in microbial pathogenicity. J Med Microbiol 1999; 48: 223-33.
39. Choay J, Petitou M, Lormeau JC, et al. Structure-activity relationship in heparin: A synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Biophys Res Commun 1983; 116: 492-9.
40. Hull C, et al. Lipopolysaccharide signals an endothelial apoptosis pathway through TNF receptor-associated factor 6-mediated activation of c-Jun NH2-terminal kinase. J Immunol 2002; 169: 2611-8.
41. Bernfield M, Hinkes MT, Gallo RL. Developmental expression of the syndecans: Possible function and regulation. Dev Suppl 1993; 205-12.
42. Gallo R, et al. Syndecans-1 and -4 are induced during wound repair of neonatal but not fetal skin. J Invest Dermatol 1996; 107: 676-83.
43. Gallo RL, Ono M, Povsic T, et al. Syndecans, cell surface heparan sulfate proteoglycans, are induced by a proline-rich antimicrobial peptide from wounds. Proc Natl Acad Sci USA 1994; 91: 11035-9.
44. Fitzgerald ML, Wang Z, Park PW, et al. Shedding of syndecan-1 and -4 ectodomains is regulated by multiple signaling pathways and mediated by a TIMP-3-sensitive metalloproteinase. J Cell Biol 2000; 148: 811-24.
45. Park PW, Pier GB, Hinkes MT, et al. Exploitation of syndecan-1 shedding by Pseudomonas aeruginosa enhances virulence. Nature 2001; 411: 98-102.
46. Park PW, Pier GB, Preston MJ, et al. Syndecan-1 shedding is enhanced by LasA, a secreted virulence factor of Pseudomonas aeruginosa. J Biol Chem 2000; 275: 3057-64.
47. Warren BL, Eid A, Singer P, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: A randomized controlled trial. JAMA 2001; 286: 1869-78.